Understanding, Avoiding, and Managing Severe Filler Complications : Plastic and Reconstructive Surgery

Journal Logo

Advanced Search
Fillers: Original Articles

Understanding, Avoiding, and Managing Severe Filler Complications

Rzany, Berthold MD, ScM; DeLorenzi, Claudio MD

Author Information

Berlin, Germany; and Kitchener, Ontario, Canada

From RZANY & HUND and the DeLorenzi Clinic.

Disclosure: Dr. Rzany is a speaker and/or advisor of the following companies: Ipsen Pharma, Galderma Laboratorium GmbH, and Merz Pharma. Dr. DeLorenzi is a paid medical director for both Allergan Canada and Merz Canada, where he is employed to assist end-users in managing filler-related adverse events. He is also a paid advisory board member for several companies, including Valeant Pharmaceuticals, Baxter, Johnson & Johnson, and Kythera.

Berthold Rzany, MD, ScM, RZANY & HUND, Privatpraxis für Dermatologie und Ästhetische Medizin, Kurfürstendamm No. 183, Berlin D-10707, Germany, [email protected]

Plastic and Reconstructive Surgery 136(5S):p 196S-203S, November 2015. | DOI: 10.1097/PRS.0000000000001760

Abstract

Summary: 

Any injectable filler may elicit moderate-to-severe adverse events, ranging from nodules to abscesses to vascular occlusion. Fortunately, severe adverse events are uncommon for the majority of fillers currently on the market. Because these are rare events, it is difficult to identify the relevant risk factors and to design the most efficacious treatment strategies. Poor aesthetic outcomes are far more common than severe adverse events. These in contrast should be easily avoidable by ensuring that colleagues receive proper training and follow best practices.

©2015American Society of Plastic Surgeons

Full Text Access for Subscribers:

Log In
ASPS Members
Log In

Not a Subscriber?

Buy
Request Permissions
Become a Society Member

You can read the full text of this article if you:

Access through Ovid